Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)
Year: 2018
Type: article
Abstract: Background: SL-701 is a novel immunotherapy comprised of synthetic peptides designed to elicit an anti-tumor immune response against targets overexpressed in glioblastoma (GBM): interleukin-13 receptor alpha-2, ephrinA2 and survivin. Updated phase 2 data are reported.
Source: Annals of Oncology
Institutions: Cleveland Clinic, University of Alabama, University of Alabama at Birmingham, Center for Neurosciences, Baylor Scott & White Health, University of Pittsburgh, Barrow Neurological Institute, Piedmont Atlanta Hospital, Henry Ford Health, University of Virginia, University of Florida Health, University of Florida, St. Joseph's Hospital and Medical Center, University of California, San Francisco, Columbia University Irving Medical Center, Stemline Therapeutics (United States), North Shore University Hospital, George Washington University, Center for Neuro-Oncology, Dana-Farber Cancer Institute
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2898097724